Enable Injections is pleased to share several notable events this February, including adding a new executive to the Enable team, new published articles (Forbes is writing about Enable!), and a new award.
Donald Kirkpatrick Joins Enable as COO
We are delighted to announce Donald Kirkpatrick has joined Enable Injections as Chief Operating Officer. Don is responsible for Product Development and Operations for the enFuse® on-body platform.
Don has over 30 years of experience in healthcare operations and product development. He joined Enable from Baxter Healthcare, where he was most recently the Head of External Contract Manufacturing, responsible for global leadership of external finished product manufacturing of electromechanical, disposable, pharmaceutical, and biologic products. Don previously served as Director, Operations Strategy where he led Operations strategy development for global plastics processes across the Baxter manufacturing plant network, as well as operations strategy and diligence for Mergers & Acquisitions, outsourcing and third-party manufacturing.
Prior to Baxter, Don held research & development, product development, operations & RAQA positions in the medical device and IVD industry at Haemonetics, Teleflex Medical, and Arrow International, including positions in the US, China, and Japan. Don earned a Bachelor of Science in Mechanical Engineering Technology from the University of Massachusetts and a Master of Business Administration from Boston College.
Drug Delivery Designed to Improve the Patient Experience
Citation: King J, “Drug Delivery Designed to Improve the Patient Experience”. ONdrugDelivery Magazine, Issue 105 (Feb 2020), pp 52-55.
Enable Injections takes a look at the delivery challenges of novel therapies for chronic diseases using a specific patient’s story as an example, going on to highlight the ways in which a novel device approach could make all the difference for patients.
Chronic illness touches everyone, it seems. Whether it is a family member, friend or co-worker, many people have some understanding of how difficult life can be while managing a chronic disease. The biotech revolution has led to many novel therapies that are changing lives. But these new therapies may come with delivery challenges that make it difficult for a patient to receive treatment. When a patient shares stories of the rigours they endure to manage their disease, it highlights the motivating factor behind novel technology like the enFuse on-body infusor platform.
A REAL PATIENT WITH A REAL STORY
The Enable Injections team recently spent time with a patient who introduced an interesting perspective on her infusions. Megan has managed a chronic autoimmune disease for more than 15 years. She is passionate about helping others who live with similar autoimmune diseases – especially young people, because she was diagnosed at the age of 18.
Megan was initially prescribed 28 pills per day for treatment, which proved to be difficult to manage and ineffective. While planning her life around her dosing schedule, she lived in a mental fog due to fatigue and was unable to travel or do other activities she loves.
At the age of 23, she began seeing a new doctor who said to her: “You are a young person and you deserve to live your life.” Megan said hearing those words was life-changing, as she thought she would never feel well again. Her new doctor prescribed a new therapy via IV administration, and she began feeling better. Even though she was required to take an afternoon off work for each treatment, she didn’t mind the inconvenience. She began to think of the three hours tethered to the IV as “me time” because the hospital infusion centre was comfortable and, over time, she came to know the staff. However, each infusion had the potential for its own challenges.
Read more at OnDrugDelivery.
enFuse® Wins a GOOD DESIGN Award
Enable Injections is pleased to announce the enFuse® has won a GOOD DESIGN® Award 2019.
Founded in 1950, GOOD DESIGN® is the world’s most prestigious, recognized, and oldest Design Awards program organized annually by The Chicago Athenaeum Museum of Architecture and Design in cooperation with the European Centre for Architecture, Art, Design and Urban Studies.
Forbes Is Talking about Enable Injections
New Forbes article, February 2020 – “Marketing to 100-Year-Olds: How Longevity Will Transform Finance, Healthcare and Education”
To learn more about Enable Injections and the enFuse® On-Body Platform, contact us.